#China #Shanghai #Healthcare Innovations #CIIE #Fosun

Fosun's Remarkable Presence at the 8th CIIE

On November 5, 2025, the much-anticipated 8th China International Import Expo (CIIE) was officially inaugurated at the National Exhibition and Convention Center in Shanghai. Celebrating its eighth consecutive year as a 'full-attendance' exhibitor, Fosun, along with its international partners, presented an impressive array of world-class innovative drugs and state-of-the-art medical devices. This year, the focus was particularly on breakthroughs in treating critical health areas such as oncology, immune-inflammatory disorders, central nervous system conditions, and kidney diseases.

Guo Guangchang's Vision for Healthcare Innovation

Guo Guangchang, Chairman of Fosun International, delivered a compelling statement emphasizing the significance of the CIIE. He portrayed the event as an essential platform for fostering innovation and advancing international collaboration in healthcare. Guo highlighted that Fosun has benefited tremendously from this ongoing showcase, transforming innovations from display items into real products while supporting foreign partners transitioning from exhibitors to investors.

Guo’s belief is clear: the upcoming years will see China playing a vital role in addressing unmet medical needs worldwide. Fosun's commitment to enhancing healthcare solutions is evident in this year’s exhibit, which includes numerous products making their debut in the healthcare sector.

Pioneering Innovations in Oncology

Among the standout innovations at this year's CIIE is the Marie Upright Particle Therapy System, a groundbreaking advancement poised to redefine cancer treatment. Unlike traditional systems, the Marie system allows for flexibility within medical facilities, enhancing precision through upright positioning during treatment—particularly beneficial for tumors located in challenging areas like the lung and abdomen. This system, which combines multiple advanced particle therapy techniques, received FDA approval in July 2025 and has made its first appearance in China at this event.

Also showcased is Fosun’s Yi Kai Da (ejilunsai injection), recognized as China's first CAR-T cell therapy. This treatment has made substantial strides in accessibility and effectiveness, approved for use in over 190 specialized treatment centers, aiding over a thousand lymphoma patients. Notably, it has achieved a remarkable survival milestone for patients treated, with one patient realizing over seven years of high-quality survival.

Further innovations in supportive cancer care include Akynzeo, the only dual-channel antiemetic globally, and Su Ke Xin, a pioneering oral thrombopoietin receptor agonist that is now approved for dual indications in China. Moreover, the innovative drug Wan Ti Le, targeted at managing serum phosphorus levels in chronic kidney disease patients, has been recognized as a finalist for Best Pharmaceutical Product at the Prix Galien 2025.

Addressing Neurological Disorders with Advanced Solutions

The rise in neurological disorders, including conditions like Parkinson's disease and epilepsy, has prompted Fosun to actively seek innovative solutions. At CIIE, Fosun presented the MRgFUS brain therapy system tailored for non-invasive treatment, attracting attention for its ability to treat common disorders effectively. Over 25,000 patients globally have benefitted from this technology so far.

In addition, Fosun introduced Ongentys (opicapone), the first once-daily COMT inhibitor approved, significantly improving the management of Parkinson's disease. Clinical trials in specialized areas in China are paving the way for broader implementation across the nation.

Harnessing Global Resources to Drive Local Innovation

Fosun's strategy involves harnessing global expertise to enhance local healthcare offerings. The ongoing commitment to transforming CIIE exhibits into market-ready products is exemplified through the Da Vinci surgical system, which has seen over 480 installations across various hospitals in China. This year, Intuitive Fosun is promoting newer surgical systems and training initiatives that bolster the skills of medical professionals.

Fosun is also embracing digital transformation by incorporating AI technologies in its operations. The PharmAID decision intelligence platform showcased at this year’s CIIE exemplifies Fosun’s leap towards smarter decision-making in drug commercialization and clinical trials. Additionally, its venture into medical aesthetics with Universkin highlights the move towards personalized skincare solutions powered by AI.

The integration of innovative resources is expected to accelerate the development of sophisticated healthcare systems in China. Guo Guangchang stated, “Fosun will continue to leverage its innovative capabilities and global partnerships to foster the pharmaceutical industry. The goal is to contribute to realizing the ambitious 'Healthy China 2030' vision.”

The showcase at CIIE not only signifies Fosun's achievements but also reflects a collective commitment towards improving global healthcare outcomes. The journey of innovation continues, with exciting prospects ahead for patients and healthcare providers alike.